Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?
Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla.
Symptomatic Sinus Bradycardia After a Treatment Course Of High-dose Oral Prednisone.
Neuromyelitis optica in a Ugandan woman: a case report.
Optic Neuritis as Isolated Manifestation of Leptomeningeal Carcinomatosis: A Case Report and Systematic Review of Ocular Manifestations of Neoplastic Meningitis.
Validity of Minimal Clinically Important Difference Values for the Multiple Sclerosis Walking Scale-12?
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study.
Interferon Beta and Long-term Disability in Multiple Sclerosis.
Immunopathology of multiple sclerosis.
Exploring myelin dysfunction in multiple system atrophy.
KCHO-1, a Novel Antineuroinflammatory Agent, Inhibits Lipopolysaccharide-Induced Neuroinflammatory Responses through Nrf2-Mediated Heme Oxygenase-1 Expression in Mouse BV2 Microglia Cells.
Clinically Significant Fatigue: Prevalence and Associated Factors in an International Sample of Adults with Multiple Sclerosis Recruited via the Internet.
Conjugal multiple sclerosis in Isfahan, Iran: a population-based study.
Fatigue Management in Multiple Sclerosis.
Stress, Multiple Sclerosis, and Everyday FunctioningA Review of the Literature with Implications for Intervention.
Serum Arsenic and Lipid Peroxidation Levels in Patients with Multiple Sclerosis.
A unified cell biological perspective on axon-myelin injury.
Toll like receptors: a new hope on the horizon to treat multiple sclerosis.
NMO spectrum disorders: how wide is the spectrum?
Fingolimod does not enhance cerebellar remyelination in the cuprizone model.
The Roles of Vitamin D and Its Analogs in Inflammatory Diseases.
Cytoplasmic sphingosine-1-phosphate pathway modulates neuronal autophagy.
Correction: An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response.
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.
Pages
« first
‹ previous
…
491
492
493
494
495
496
497
498
499
…
next ›
last »